For research use only. Not for therapeutic Use.
Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
| Catalog Number | I047356 |
| Purity | ≥95% |
| Reference | [1] Hwang M, et,al. J Clin Pharmacol. 2023 Jul;63(7):817-829. |
